Organon & Co. (NYSE:OGN) Cut to Hold at Wall Street Zen

Organon & Co. (NYSE:OGN) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday.

A number of other analysts also recently weighed in on the stock. Barclays initiated coverage on shares of Organon & Co. in a report on Tuesday, December 9th. They issued an “underweight” rating and a $7.50 price target for the company. JPMorgan Chase & Co. cut their price objective on shares of Organon & Co. from $14.00 to $12.00 and set an “underweight” rating for the company in a research report on Tuesday, November 11th. Piper Sandler cut shares of Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 target price for the company. in a research note on Monday, October 27th. Morgan Stanley lowered their price target on Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 11th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Organon & Co. in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and four have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Reduce” and an average target price of $8.38.

Organon & Co. Stock Performance

OGN opened at $8.51 on Friday. The firm has a market capitalization of $2.21 billion, a P/E ratio of 4.43, a price-to-earnings-growth ratio of 1.84 and a beta of 0.58. The stock’s 50 day moving average price is $7.80 and its two-hundred day moving average price is $8.73. The company has a quick ratio of 1.20, a current ratio of 1.75 and a debt-to-equity ratio of 9.69. Organon & Co. has a 12-month low of $6.18 and a 12-month high of $17.23.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Monday, November 10th. The company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.93 by $0.08. Organon & Co. had a return on equity of 143.47% and a net margin of 7.95%.The company had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same period in the previous year, the company earned $1.38 earnings per share. On average, equities analysts forecast that Organon & Co. will post 3.68 earnings per share for the current year.

Institutional Trading of Organon & Co.

Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in shares of Organon & Co. by 2.7% during the fourth quarter. Vanguard Group Inc. now owns 36,916,382 shares of the company’s stock valued at $264,690,000 after acquiring an additional 987,979 shares during the period. State Street Corp grew its holdings in shares of Organon & Co. by 6.0% in the 2nd quarter. State Street Corp now owns 9,520,594 shares of the company’s stock worth $92,159,000 after purchasing an additional 540,478 shares during the last quarter. Nordea Investment Management AB increased its position in shares of Organon & Co. by 1.1% during the 2nd quarter. Nordea Investment Management AB now owns 4,904,076 shares of the company’s stock worth $48,281,000 after purchasing an additional 53,733 shares in the last quarter. UBS Group AG lifted its holdings in Organon & Co. by 55.2% during the 4th quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock valued at $30,795,000 after purchasing an additional 1,527,492 shares during the last quarter. Finally, AQR Capital Management LLC lifted its holdings in Organon & Co. by 28.3% during the 3rd quarter. AQR Capital Management LLC now owns 4,176,144 shares of the company’s stock valued at $43,641,000 after purchasing an additional 921,260 shares during the last quarter. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.